Identifying Potential Qsymia Patients

Qsymia can help you treat many of the patients you see in your practice1,2

Qsymia has been clinically proven to provide effective and well-tolerated treatment for a range of overweight and obese patient types1,2

Qsymia gives a range of overweight and obese patients the power to lose

Qsymia was studied in 2 large trials supporting FDA approval that involved 3754 patients whose BMI was 27 kg/m2 or greater. For the subjects in the 2 trials the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Presented here are weight loss and waist circumference reduction in the subset of subjects (N=2076) with a baseline BMI of 27 kg/m2 or greater, and who used study drug for the planned 56-week course of treatment. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg, phentermine 7.5 mg/topiramate 46 mg, or phentermine 15 mg/topiramate 92 mg. In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your patients’ results may vary depending on their BMI, diet, activity, dose of Qsymia, and other factors.

In a subset analysis, patients with a BMI ≥30 kg/m2 taking the recommended dose of Qsymia lost an average of approximately 10% of their body weight after 1 year.

The titration schedule for the studies was faster than what is recommended in the Qsymia package insert. Subjects took the 3.75 mg/23 mg strength for one week, then the 7.5 mg/46 mg strength for one week (unless randomized to this arm); then the 11.25 mg/69 mg strength for one week, followed by the 15 mg/92 mg strength.1,2

 
1

Patient Type 1: Comorbid

Qsymia provides reliable efficacy for obese patients with comorbidities1,2

 

*Statistical significance achieved (type 2 diabetes: P=.0115; hypertension: P<.0001; P values are from Fisher’s exact test).2 Qsymia is not indicated for the treatment of type 2 diabetes, hypertension, dyslipidemia, or depression.

 
BACK TO TOP

2

Patient Type 2: Difficult to Treat

Diffcult-to-treat populations significantly reduced weight in clinical trials1,2

 
BACK TO TOP

3

Patient Type 3: BMI Range

Qsymia helped patients successfully lose weight across a range of BMI1,2

 
BACK TO TOP

Clinically proven weight loss — review the data

Review the results from the two 56-week Qsymia clinical studies1,2

Prescribing and dosing for Qsymia

Initiating therapy and ongoing assessment of Qsymia patients

Important Safety Information

Qsymia is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

VIEW ALL +
Online ordering with convenient home delivery.
You pay only $98 across all doses.§
Exclusively priced for cash patients. Additional shipping and handling costs will apply.
LEARN MORE
LEARN MORE AND SAVE